These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7827902)

  • 121. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography.
    Francis DL; Freeman A; Visvikis D; Costa DC; Luthra SK; Novelli M; Taylor I; Ell PJ
    Gut; 2003 Nov; 52(11):1602-6. PubMed ID: 14570730
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer.
    Burt BM; Humm JL; Kooby DA; Squire OD; Mastorides S; Larson SM; Fong Y
    Neoplasia; 2001; 3(3):189-95. PubMed ID: 11494112
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Decision analysis for the cost-effective management of recurrent colorectal cancer.
    Park KC; Schwimmer J; Shepherd JE; Phelps ME; Czernin JR; Schiepers C; Gambhir SS
    Ann Surg; 2001 Mar; 233(3):310-9. PubMed ID: 11224617
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Peritoneal recurrence of colon cancer detected by positron emission tomography: report of a case.
    Yasuda S; Makuuchi H; Sadahiro S; Mukai M; Ishida H; Tokunaga N; Kimura T; Tajima T; Shohtsu A
    Surg Today; 1999; 29(7):633-6. PubMed ID: 10452242
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Current role of positron emission tomography in thoracic oncology.
    Lowe VJ; Naunheim KS
    Thorax; 1998 Aug; 53(8):703-12. PubMed ID: 9828860
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.
    Flanagan FL; Dehdashti F; Ogunbiyi OA; Kodner IJ; Siegel BA
    Ann Surg; 1998 Mar; 227(3):319-23. PubMed ID: 9527052
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images.
    Bengel FM; Ziegler SI; Avril N; Weber W; Laubenbacher C; Schwaiger M
    Eur J Nucl Med; 1997 Sep; 24(9):1091-8. PubMed ID: 9283100
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
    Brock CS; Meikle SR; Price P
    Eur J Nucl Med; 1997 Jun; 24(6):691-705. PubMed ID: 9169580
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
    Rigo P; Paulus P; Kaschten BJ; Hustinx R; Bury T; Jerusalem G; Benoit T; Foidart-Willems J
    Eur J Nucl Med; 1996 Dec; 23(12):1641-74. PubMed ID: 8929320
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management.
    Wilson CB; Young HE; Ott RJ; Flower MA; Cronin BF; Pratt BE; McCready VR; Horwich A
    Eur J Nucl Med; 1995 Jun; 22(6):508-13. PubMed ID: 7556294
    [TBL] [Abstract][Full Text] [Related]  

  • 132. [F-18 fluorodeoxyglucose positron emission tomography in colorectal carcinoma].
    Jörg L; Langsteger W
    Wien Med Wochenschr; 2002; 152(11-12):276-9. PubMed ID: 12138655
    [TBL] [Abstract][Full Text] [Related]  

  • 133. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer.
    Beets G; Penninckx F; Schiepers C; Filez L; Mortelmans L; Kerremans R; Aerts R; De Roo M
    Br J Surg; 1994 Nov; 81(11):1666-70. PubMed ID: 7827902
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
    Hung GU; Shiau YC; Tsai SC; Chao TH; Ho YJ; Kao CH
    Anticancer Res; 2001; 21(2B):1375-8. PubMed ID: 11396217
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences.
    Imdahl A; Reinhardt MJ; Nitzsche EU; Mix M; Dingeldey A; Einert A; Baier P; Farthmann EH
    Langenbecks Arch Surg; 2000 Mar; 385(2):129-34. PubMed ID: 10796051
    [TBL] [Abstract][Full Text] [Related]  

  • 138.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 139.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 140.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.